MPR2d
Wearable Furosemide Delivery System Approved for CKD Patients
The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...
The Pharma Letter5d
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The Furoscix 80 mg/10 ml subcutaneous injection is intended for oedema in adult CKD patients, including those with nephrotic ...
The American Journal of Managed Care7d
FDA Expands Furosemide Injection Label to Treat Edema in CKD
Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.
The Pharma Letter7d
FDA nod for scPharmaceuticals’ Furoscix sNDA
Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...
TD Cowen Keeps Their Buy Rating on scPharmaceuticals (SCPH)
TD Cowen analyst Stacy Ku maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) today and set a price target of $25.00.Discover ...
scPharmaceuticals announces FDA approval of Furoscix indication expansion
Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...